公开(公告)号：WO2013126006A1

公开(公告)日：2013-08-29

申请号：PCT/SE2013/050139

申请日：2013-02-19

Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Inventor： BERGHARD, Charlotta ,  BERGLUND, Magnus ,  STRÖMBERG, Patrik ,  LINDBORG, Malin ,  GUNNERIUSSON, Elin ,  FELDWISCH, Joachim

IPC: C07K14/47 ,  A61K38/17 ,  A61P9/00 ,  A61P29/00

CPC classification number: A61K38/164 ,  A61K38/00 ,  A61K38/16 ,  C07K14/00 ,  C07K14/195 ,  C07K14/315 ,  C07K14/47

Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM , which motif consists of an amino acid sequence selected from i) EX 2 X 3 X 4 A X 6 X 7 EID X 11 LPNL X 16 X 17 X 18 QW X 21 AFIX 25 X 26 LX 28 D, and ii) an amino acid sequence which has at least 86 % identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.

Abstract translation: 本发明涉及C5结合多肽，其包含C5结合基序，BM，其基序由选自i）EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D的氨基酸序列组成，以及ii）与SEQ ID NO：1至少86％同一性的氨基酸序列 i）中定义的序列，其中所述多肽与C5结合。 本发明还涉及用于治疗的C5结合多肽，例如用于治疗C5相关病症，以及治疗方法。

公开(公告)号：WO2018178392A1

公开(公告)日：2018-10-04

申请号：PCT/EP2018/058448

申请日：2018-04-03

Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Inventor： FELDWISCH, Joachim ,  LINDBORG, Malin ,  NILSSON, Joakim ,  NORDLING, Erik ,  SVENSSON, Robert

IPC: C07K14/00 ,  C07K14/31

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif ( BM ) EX 2 X 3 X 4 X 5 X 6 X 7 EIX 10 X 11 LPNLX 16 RX 18 QYX 21 AFIX 25 X 26 LX 28 D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.